American Assets Trust reported Q2 2026 earnings that missed estimates, but management reaffirmed its full-year FFO guidance, expecting stronger results in the second half as signed leases begin. The company faces execution risk tied to lease commencements, with leverage at 6.7x net debt/EBITDA, though liquidity and debt maturity schedules reduce near-term financial pressure. The dividend yield stands at 6%, but a high payout ratio limits dividend growth unless lease execution and cash flow improve. Despite these challenges, the stock has gained over 9% in the past year and nearly 20% year-to-date, reflecting cautious optimism among investors.
Bunzl PLC reported stronger-than-expected financial results with an EPS of $0.60, surpassing the $0.56 consensus. Revenue reached $8.04 billion, driven by a 3.2% underlying growth, especially in North America. The operating margin improved to 7.3%, p...
Palo Alto Networks is set to report strong earnings per share (EPS) of $0.98 and revenue of $3.35 billion for the upcoming quarter, reflecting significant growth from last year. Investor optimism is driven by robust cybersecurity sector trends and a ...
Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...
Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...
Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...
